On June 17, the appointment ceremony of scientific advisors of Analytical Biosciences took place in the Beijing office. Analytical Biosciences invited Professor Runsheng Chen from Institute of Biophysics of the Chinese Academy of Sciences, Professor Fuchou Tang from Peking University, and Professor Zemin Zhang from Peking University to join its Scientific Advisory Board. The goal of these appointment is to advance the research and technology capacities and to enhance the impact of single-cell sequencing and bioinformatics. The appointment ceremony was hosted by Mr. Tao Hong, Chief Operating Officer of Analytical Biosciences. On behalf of the company, he issued letters of appointment to the three advisors.
Prof. Runsheng Chen is one of the pioneering scholars in computational biology and bioinformatics in China. Prof. Chen has led his bioinformatics group to a series of paramount successes, including the whole genome assembly and annotation for T. tengcongensis B4 (the first bacterium genome completely sequenced in China), the 1% Human Genome Project, and the Draft Sequence of the Rice Genome. Since 2001, Prof. Chen has rapidly expanded his interests to the investigation of noncoding RNAs and has established multiple widely used noncoding RNA databases. Prof. Chen has published more than 200 papers and has won the winner of "Kotani Prize". Prof. Chen is a member of the Chinese National Academy of Sciences.
Prof. Fuchou Tang pioneered the development of single cell RNA sequencing in the world, and has guided his laboratory in developing multiple successful cutting-edge single cell genomics techonologies including single cell DNA methylome sequencing, single cell chromatin accessibility sequencing, and single cell multiple omics sequencing. His lab also studies the gene regulation network in human early embryos and germline cells. He has published numerous high-impact studies in Cell, Nature, and Science, and has been widely recognized as a leading single cell biologist in the world. His work has been awarded the “Top 10 Scientific and Technological Advances of China” for both 2014 and 2015.
At the ceremony, Prof. Zemin Zhang presented the company vision as well as the current state of the research and development capabilities to Profs. Chen and Tang, and outline how the new advisor might help the company. Both Prof. Chen and Prof. Tang expressed their enthusiastic view towards the scientific and business plan of the company and then stated their commitment to the future success of Analytical Biosciences. After the official signing of the scientific advisory agreements, all three advisors toured the computational and experimental facilities of the company, and each of them provided constructive feedbacks. Mr. Hong expressed how the entire company staff members were excited by the participation of all three scientific advisors and expected the successful partnership will propel the success of Analytical Biosciences.
汤富酬教授主要从事人类早期胚胎以及生殖系细胞发育的单细胞功能基因组学研究。他的工作开启了单细胞转录组测序时代，建立了单细胞转录组高通量测序、单细胞 DNA 甲基化组高通量测序、单细胞染色质状态组高通量测序、单细胞多组学平行高通量测序等技术，并利用这一技术体系对人类早期胚胎以及生殖系细胞进行了深入、系统的分析。曾在Nature, Science, Cell等杂志发表了具有国际影响力的学术成果。其中两项研究工作获评 2014 年度中国科学十大进展和 2015 年度中国科学十大进展。2013 年获得国家自然科学基金委优秀青年基金、 2016 年获得国家自然科学基金委杰出青年基金。还获得吴杨奖基础医学奖、谈家桢生命科学创新奖、国家科学技术进步奖等奖励。
On the June 10, Mr. Boxi Kang, head of the Bioinformatics Department of Analytical Biosciences, gave a lecture entitled “A Framework for Real-time Analysis and Visualization of Large Single-cell RNA-seq Data” on the Cold Spring Harbor Asia Conference (Suzhou) on the Scientific and Technical Advances in Cancer Immunology.
The rapid and accurate annotation of single-cell data is becoming an analytical challenge. The current unsupervised-clustering-annotation approaches are time- and labor- consuming, and also cannot based on a uniform analysis standard. Like the human genome references that make re-sequencing possible, supervised projection of newly-generated data onto annotated labels has become more efficient and practical with the fast accumulation of single cell RNA sequencing data. Based on the Gamma-Poisson distribution of single cell gene expression data, Chenwei Li, Boxi Kang and colleagues established an entropy-test for the determine of single-cell gene expression variability. Applying such entropy statistic, they built SciBet (Single Cell Identifier Based on Entropy Test), a Bayesian classifier that accurately predicts cell identity for any randomly sequenced cells. Boxi demonstrated that SciBet outperforms existing tools in accuracy, robustness, speed and scalability in the presentation.
Mr. Kang’s enthusiastic lecture attracted a wide range of interests from the audience, including the world's top immunologists and computational biologists, and triggered extensive discussion. This work was also presented as a poster during the meeting.
Cold Spring Harbor Laboratory (CSHL) is a private, not-for-profit research and education institution at the forefront of efforts in molecular biology and genetics. CSHL meetings and courses are widely praised for propelling the advancement of modern biology. Cold Spring Harbor Asia conferences are held at Suzhou Dushu Lake Conference Center in Suzhou, China. The series of conference has become one of the most influential forums on life science in China and Asia Pacific. This particular meeting was co-organized by Zemin Zhang, a co-founder of Analytical Biosciences.
6月10日，北京百奥智汇科技有限公司生物信息部负责人康博熙在亚洲冷泉港会议（苏州）：Scientific and Technical Advances in Cancer Immunology上给出学术报告，题目为“A Framework for Real-time Analysis and Visualization of Large Single-cell RNA-seq Data”。
当前，无监督聚类法（unsupervised clustering）通常基于基因表达谱的相似性而对单个细胞进行分类，帮助科学家解读细胞群体异质性，发现新的细胞类型。但是，随着单细胞组学的研究进展和数据积累，将新产出的单细胞数据与参考数据集比对，类似于在获得参考基因组序列的条件下开展重测序分析，是未来单细胞组学研究的高效途径。基于单细胞基因表达的gamma-poisson分布，李辰威、康博熙等人建立了Entropy-test（E-test）方法提取存在表达差异的特征基因。在此基础上，他们进一步开发了SciBet (Single-Cell Identifier Based on E-Test)，一种基于贝叶斯分类器的细胞类型判读的生物信息工具。与现有其他工具相比这一技术速度极快，在处理超大数据量时优势明显。这一工具可以实现单细胞数据跨物种、跨实验平台的比较，同时E-test提取的基因向量可延伸应用到降维、去除批次效应以及对组织整体数据的去卷积分析等。
美国冷泉港实验室（Cold Spring Harbor Laboratory）是一家专门从事生命科学基础研究，教育培训和科普知识传播的综合性研究所，举办大量的国际学术会议和研讨班是这一研究机构的重要特色并广受世界赞誉。冷泉港亚洲（Cold Spring Harbor Asia）是美国冷泉港实验室的海外分支机构。它位于苏州独墅湖畔，在亚太地区创造全新国际学术会议系列平台，是中国及亚太地区最具影响力的生命科学论坛之一。
Analytical BioSciences Limited, the single-cell big data company, has raised the Series A funding led by IDG Capital, a leading investment firm specialized in TMT & Healthcare. Dr. Zemin Zhang, the founder of the company, says that the fund will be used to accelerate the development of single-cell genomic capabilities for medicine research, especially the establishment of single-cell big data platform, intelligent analysis pipeline and in-depth interpretation.
IDG Capital says, “We have been closely focusing on the development of cutting-edge technology in the field of life medicine and strongly supporting technology transformation. Among which single-cell big data is one of the key areas we invested. Dr. Zemin Zhang has rich experience in the pharmaceutical industry and also has a large number of internationally leading research results. We are optimistic about the scientific strength and commercial potential of the Analytical Biosciences team. We will continue to support the company to become the leading company in China and over the world. "
Emerging single-cell sequencing technologies can now readily profile thousands of cells, and data is accumulating rapidly. However, few biotech companies in China can efficiently process such mass data and interpret it with biological insights. At present, Analytical Biosciences is in the leading position in single-cell medical genomics with advanced bioinformatics technologies. The IDG Capital's funding will support us to sustain our leadership in this territory.
Analytical BioSciences Limited aims to unleash the power of genomics and bioinformatics in understanding major human diseases, providing capacities on (1) Single-cell sequencing, (2) Cancer genomics; (3) Bioinformatics and biological data mining; (4) Drug targets and biomarkers discovery. Target customers are mainly researchers and clinicians from biomedical research institutes, hospitals and international pharmaceutical companies. The company was founded in December 2018, and based in Beijing, China. For more information, please access to www.abiosciences.com or contact: +86 10 62566819, firstname.lastname@example.org.
The management team of Analytical Biosciences Limited has comprehensive backgrounds in genomics, bioinformatics, information technology and investment, and rich experiences in biotechnology and pharmaceuticals. Dr. Zemin Zhang, the founder of the company, spent over 16 years at Genentech/Roche, leading the cancer genomics and bioinformatics group to discover anticancer targets and. After Join in Peking University, his lab developed single-cell sequencing technologies to delineate the detailed composition and functional status of the tumor microenvironment, the related studies were published on Nature, Cell and Nature Genetics, Nature Biotechnology, etc. He is also an inventor for 60 issued US patents, and has directly contributed to the initial finding of the molecular targets of multiple cancer therapeutic agents in clinical trials.
Founded in 1992, IDG Capital is a leading investment firm focused on developing extraordinary companies through our expertise in private equity, venture capital and mergers & acquisitions. Since its inception, IDG Capital has expanded into thirteen cities around the world. Accumulated assets under management have grown from US$10 million in 1992 to approximately US$20 billion today. IDG Capital focuses on Technology, Media and Telecommunications (TMT), Consumer and Entertainment, Healthcare, Advanced Manufacturing/Clean-Tech and Energy. To date, IDG Capital has invested in more than 800 companies and made over 180 successful exits across the globe through IPOs and M&A. For more information, please visit http://www.idgcapital.com/
2019年6月，百奥智汇科技有限公司（Analytical BioSciences Limited）宣布近期完成来自IDG资本的A轮投资。
百奥智汇核心创始团队拥有基因组学、生物信息学、ICT和投资等专业背景，在生物技术，制药等行业经验丰富。创始人兼科学顾问张泽民教授曾长期供职于美国著名药企Genentech，并担任生物信息部门首席科学家，是国际知名的肿瘤基因组学家。2014年回国后他利用单细胞转录组技术在肿瘤免疫研究领域取得突破，曾在Nature、Cell、Nature Medicine、Nature Biotechnology等杂志以通讯作者的身份发表多篇重量级论文。同时他在肿瘤方面的研究已获得60项美国专利和多项欧洲专利。
联系方式：电话：+86 10 62566819，电邮：email@example.com.
On June 29, 2019, the fifth precision medicine and gene sequencing conference was held in the academic hall of Peking Union Medical College. The conference was co-sponsored by seqChina, Peking Union Medical College Hospital and Beijing Medical Award Foundation. Prof. Runsheng Chen and Prof. Zemin Zhang were invited to attend the conference and presented the plenary lectures, which received extensive attention, discussion and recognition from the participants.
As the President of the conference, Prof. Runsheng Chen, academician of Chinese Academy of Sciences and scientific advisor of Analytical Biosciences, gave the opening speech. Prof. Chen said that the development of precision medicine is bound up with multiple categories of genomic information, and their application is playing more essential role in life sciences. The medical research is stepping into accuracy and concrete through changing individual-oriented genomics to cell-oriented genomics. With the advancement of gene sequencing technology, precision medicine will affect more widely on people's daily lives.
Zemin Zhang, professor of Peking University and founder of Analytical Biosciences, gave a report entitled "Dynamic properties of tumor-infiltrating immune cells revealed by single cell sequencing". Prof. Zhang introduced the his studies focus on cancer immunology using cutting-edge single-cell transcriptome and bioinformatics, including the T cell landscapes of liver cancer, lung cancer and colorectal cancer using smart-seq2 technology, and the landscape of total CD45+ immune cells in liver cancer combining smart-seq2 and 10x Genomics technology. These studies systematically characterized the functional groups of immune cells in cancer, paving a path to the immune classification of cancer patients and the discovery of novel immunotherapies.
Prof. Zemin Zhang also introduced the current state of Analytical Biosciences, underlined the achievements and advantages of bioinformatics development, and such tools have been utilized in the above cancer immunology studies. He said our bioinformatics toolkits can be applied on the expanding scope of single-cell genomic research, thus promoting single-cell sequencing to play an increasingly important role in the development of precision medicine.
© Analytical Biosciences Limited. All rights reserved.